LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION April 9, 2015 TO: Honorable Myra Crownover, Chair, House Committee on Public Health FROM: Ursula Parks, Director, Legislative Budget Board IN RE:HB21 by Kacal (relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. The bill would amend the Health and Safety Code to allow eligible patients access to investigational drugs, biological products, or devices if certain conditions are met. The bill would authorize certain actions by manufacturers, health insurers, and physicians to ensure access to such products. It is anticipated that the duties and responsibilities of implementing agencies would be accomplished through existing resources. Local Government Impact No fiscal implication to units of local government is anticipated. Source Agencies:696 Department of Criminal Justice, 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission LBB Staff: UP, ADe, ER, NB, WP, VJC, EMo, PFe
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION
April 9, 2015
TO: Honorable Myra Crownover, Chair, House Committee on Public Health FROM: Ursula Parks, Director, Legislative Budget Board IN RE:HB21 by Kacal (relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.), Committee Report 1st House, Substituted
TO: Honorable Myra Crownover, Chair, House Committee on Public Health
FROM: Ursula Parks, Director, Legislative Budget Board
IN RE: HB21 by Kacal (relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.), Committee Report 1st House, Substituted
Honorable Myra Crownover, Chair, House Committee on Public Health
Honorable Myra Crownover, Chair, House Committee on Public Health
Ursula Parks, Director, Legislative Budget Board
Ursula Parks, Director, Legislative Budget Board
HB21 by Kacal (relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.), Committee Report 1st House, Substituted
HB21 by Kacal (relating to authorizing patients with certain terminal illnesses to access certain investigational drugs, biological products, and devices that are in clinical trials.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
The bill would amend the Health and Safety Code to allow eligible patients access to investigational drugs, biological products, or devices if certain conditions are met. The bill would authorize certain actions by manufacturers, health insurers, and physicians to ensure access to such products. It is anticipated that the duties and responsibilities of implementing agencies would be accomplished through existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.
Source Agencies: 696 Department of Criminal Justice, 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission
696 Department of Criminal Justice, 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission
LBB Staff: UP, ADe, ER, NB, WP, VJC, EMo, PFe
UP, ADe, ER, NB, WP, VJC, EMo, PFe